National Development and Reform Commission Investigates New Listed Drug Prices
2021-02-23 11:22:30
After the media disclosed that some drugs had risen sharply before the publication of the new national medical insurance catalog, the National Development and Reform Commission issued a notice a few days ago to carry out special investigations on the ex-factory price of some drugs, and new drugs entering the national medical insurance list became the investigation focus.
Some media reports said that some drug companies raised their drug prices in advance before the product entered the basic drug list. The survey also appears to be quite targeted.
It is reported that the scope of the survey is the new medicines that have entered the National Health Insurance Catalogue and some of the drugs that have been stipulated as having the highest retail price limit, involving more than 900 manufacturing enterprises and nearly 900 varieties. The investigation will be organized by the National Drug Development and Reform Commission's Drug Price Assessment Center and will obtain basic information such as the actual ex-factory price of the drug and the financial operating status of the production company through field inspections of financial accounts and original sales vouchers. The investigation will be dismissed, refusal to report, false reports, and errors. Manufacturers reporting drug ex-factory prices will be investigated and dealt with according to law.
According to sources, the special price survey is not a price inspection in the ordinary sense, nor is it responsible for price inspections by the National Development and Reform Commission's price inspection department. This time, the investigation of the ex-factory price of pharmaceuticals may be for the upcoming "Pharmaceutical Price Management." Method (Exposure Draft) "Pave the way.
A source from the pharmaceutical industry disclosed to reporters that the investigation by the National Development and Reform Commission on the ex-factory price of drugs was obviously a precursor to heavy drug prices, but he also stated that “high prices of medicines in the Medicare Catalogue and the increase in the circulation of medicines make drugs more expensive. The price remains 'high,' and the state will surely introduce measures to control it. However, under the system of 'taking medicine to support the doctor', doctors are more interested in high-priced drugs. Even if the price of ex-factory drugs is thoroughly investigated, ordinary people still find it difficult to use cheap and effective products. Good medicine."
Some media reports said that some drug companies raised their drug prices in advance before the product entered the basic drug list. The survey also appears to be quite targeted.
It is reported that the scope of the survey is the new medicines that have entered the National Health Insurance Catalogue and some of the drugs that have been stipulated as having the highest retail price limit, involving more than 900 manufacturing enterprises and nearly 900 varieties. The investigation will be organized by the National Drug Development and Reform Commission's Drug Price Assessment Center and will obtain basic information such as the actual ex-factory price of the drug and the financial operating status of the production company through field inspections of financial accounts and original sales vouchers. The investigation will be dismissed, refusal to report, false reports, and errors. Manufacturers reporting drug ex-factory prices will be investigated and dealt with according to law.
According to sources, the special price survey is not a price inspection in the ordinary sense, nor is it responsible for price inspections by the National Development and Reform Commission's price inspection department. This time, the investigation of the ex-factory price of pharmaceuticals may be for the upcoming "Pharmaceutical Price Management." Method (Exposure Draft) "Pave the way.
A source from the pharmaceutical industry disclosed to reporters that the investigation by the National Development and Reform Commission on the ex-factory price of drugs was obviously a precursor to heavy drug prices, but he also stated that “high prices of medicines in the Medicare Catalogue and the increase in the circulation of medicines make drugs more expensive. The price remains 'high,' and the state will surely introduce measures to control it. However, under the system of 'taking medicine to support the doctor', doctors are more interested in high-priced drugs. Even if the price of ex-factory drugs is thoroughly investigated, ordinary people still find it difficult to use cheap and effective products. Good medicine."
Fluorescent Pcr Instruments,Quantitative Polymerase Chain Reaction,Fluorescent Quantitative Pcr System,Fluorescent Real Time Pcr Instruments
Jiangsu Dinai Bioengineering Co.,ltd. , https://www.dinaipcr.com